Skip to main content
Top
Published in: Targeted Oncology 4/2014

01-12-2014 | Original Research

Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysis

Authors: Zhijun Li, Yongjun Zhang, Wenlong Bao, Chuming Jiang

Published in: Targeted Oncology | Issue 4/2014

Login to get access

Abstract

The detection of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer tissues is necessary for effective treatment with EGFR tyrosine kinase inhibitors. However, tumor tissues may not be available in all situations. Studies have evaluated the potential use of serum or plasma for detecting the EGFR mutation status, but the results have been inconclusive. Here, a meta-analysis was performed to determine whether blood samples could serve as substitutes for tissue specimens in detecting the EGFR mutation status. Databases, including PubMed and Embase, were searched for relevant studies published from 2005 to 2013 that included true-positive, false-positive, true-negative, and false-negative values of the EGFR mutation status of the blood compared with tissue specimens. Summary receiver operating characteristic curves were developed to explore the threshold effect. Spearman’s correlation coefficient was calculated to analyze the heterogeneity between studies. Pooled sensitivity and specificity were evaluated using Meta-DiSc version 1.4. Thirteen articles involving 1,591 cases were enrolled, with a pooled sensitivity and specificity of 64.5 % (95 % CI = 0.605–0.683) and 88.5 % (95 % CI = 0.863–0.904), respectively. Heterogeneity among the studies was caused by factors other than threshold effect. The findings were influenced by test method (p = 0.0354). Blood samples had a high specificity and relatively low sensitivity for detecting EGFR mutations compared to tumor tissues. The results of this meta-analysis suggest that peripheral blood is insufficient as a substitute for tumor tissues in detecting EGFR mutations in clinical practice.
Literature
3.
go back to reference Molina JR, Yang P, Cassivi SD et al (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584–594PubMedCentralPubMedCrossRef Molina JR, Yang P, Cassivi SD et al (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83:584–594PubMedCentralPubMedCrossRef
4.
go back to reference Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98PubMedCrossRef Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98PubMedCrossRef
5.
go back to reference Scagliotti GV, Selvaggi G, Novello S, et al. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004;10:4227 s-4232s. Scagliotti GV, Selvaggi G, Novello S, et al. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004;10:4227 s-4232s.
6.
go back to reference Fujino S, Enokibori T, Tezuka N et al (1996) A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 32A:2070–2074PubMedCrossRef Fujino S, Enokibori T, Tezuka N et al (1996) A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 32A:2070–2074PubMedCrossRef
7.
go back to reference Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353:123–132PubMedCrossRef Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353:123–132PubMedCrossRef
8.
go back to reference Bell DW, Lynch TJ, Haserlat SM et al (2005) Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23:8081–8092PubMedCrossRef Bell DW, Lynch TJ, Haserlat SM et al (2005) Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23:8081–8092PubMedCrossRef
9.
go back to reference Chen G, Feng J, Zhou C et al (2013) Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol 24:1615–1622PubMedCrossRef Chen G, Feng J, Zhou C et al (2013) Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol 24:1615–1622PubMedCrossRef
10.
go back to reference Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246PubMedCrossRef Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246PubMedCrossRef
11.
go back to reference Paez JG, Jänne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRef Paez JG, Jänne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRef
12.
go back to reference Sequist LV, Martins RG, Spigel D et al (2008) First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26:2442–2449PubMedCrossRef Sequist LV, Martins RG, Spigel D et al (2008) First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26:2442–2449PubMedCrossRef
13.
go back to reference Costa DB, Kobayashi S, Tenen DG et al (2007) Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58:95–103PubMedCentralPubMedCrossRef Costa DB, Kobayashi S, Tenen DG et al (2007) Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58:95–103PubMedCentralPubMedCrossRef
14.
go back to reference Sozzi G, Conte D, Leon M et al (2003) Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21:3902–3908PubMedCrossRef Sozzi G, Conte D, Leon M et al (2003) Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21:3902–3908PubMedCrossRef
15.
go back to reference He C, Liu M, Zhou C et al (2009) Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer 125:2393–2399PubMedCrossRef He C, Liu M, Zhou C et al (2009) Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer 125:2393–2399PubMedCrossRef
16.
go back to reference Brevet M, Johnson ML, Azzoli CG et al (2011) Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitor. Lung Cancer 73:96–102PubMedCentralPubMedCrossRef Brevet M, Johnson ML, Azzoli CG et al (2011) Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitor. Lung Cancer 73:96–102PubMedCentralPubMedCrossRef
17.
go back to reference Mack PC, Holland WS, Burich RA et al (2009) EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol 4:1466–1472PubMedCrossRef Mack PC, Holland WS, Burich RA et al (2009) EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol 4:1466–1472PubMedCrossRef
18.
go back to reference Yung TK, Chan KC, Mok TS et al (2009) Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 15:2076–2084PubMedCrossRef Yung TK, Chan KC, Mok TS et al (2009) Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 15:2076–2084PubMedCrossRef
19.
go back to reference Kimura H, Suminoe M, Kasahara K et al (2007) Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 97:778–784PubMedCentralPubMedCrossRef Kimura H, Suminoe M, Kasahara K et al (2007) Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 97:778–784PubMedCentralPubMedCrossRef
20.
go back to reference Bai H, Mao L, Wang HS et al (2009) Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non–small-cell lung cancer. J Clin Oncol 27:2653–2659PubMedCrossRef Bai H, Mao L, Wang HS et al (2009) Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non–small-cell lung cancer. J Clin Oncol 27:2653–2659PubMedCrossRef
21.
go back to reference Kim ST, Sung JS, Jo UH et al (2013) Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)? Med Oncol 30:328PubMedCrossRef Kim ST, Sung JS, Jo UH et al (2013) Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)? Med Oncol 30:328PubMedCrossRef
22.
go back to reference Huang Z, Wang ZJ, Bai H et al (2012) The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thoracic Cancer 3:334–340CrossRef Huang Z, Wang ZJ, Bai H et al (2012) The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thoracic Cancer 3:334–340CrossRef
23.
go back to reference Zhao X, Han RB, Zhao J et al (2013) Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration 85:119–125PubMedCrossRef Zhao X, Han RB, Zhao J et al (2013) Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration 85:119–125PubMedCrossRef
24.
go back to reference Song GH, Ren J, Zhang LJ et al (2010) Low correspondence of EGFR mutations in tumor tissue and paired serum of non-small-cell lung cancer patients. Chin J Cancer Res 22:27–31CrossRef Song GH, Ren J, Zhang LJ et al (2010) Low correspondence of EGFR mutations in tumor tissue and paired serum of non-small-cell lung cancer patients. Chin J Cancer Res 22:27–31CrossRef
25.
go back to reference Ellison G, Zhu G, Moulis A et al (2013) EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol 66:79–89PubMedCentralPubMedCrossRef Ellison G, Zhu G, Moulis A et al (2013) EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol 66:79–89PubMedCentralPubMedCrossRef
26.
go back to reference Jiang B, Liu F, Yang L et al (2011) Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer. J Int Med Res 39:1392–1401PubMedCrossRef Jiang B, Liu F, Yang L et al (2011) Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer. J Int Med Res 39:1392–1401PubMedCrossRef
27.
go back to reference Kim ST, Jung HY, Sung JS et al (2013) Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer? Am J Clin Oncol 36:57–63PubMedCrossRef Kim ST, Jung HY, Sung JS et al (2013) Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer? Am J Clin Oncol 36:57–63PubMedCrossRef
28.
go back to reference Hu C, Liu X, Chen Y et al (2012) Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis. Oncol Rep 28:1815–1821PubMed Hu C, Liu X, Chen Y et al (2012) Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis. Oncol Rep 28:1815–1821PubMed
29.
go back to reference Goto K, Ichinose Y, Ohe Y et al (2012) Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 7:115–121PubMedCrossRef Goto K, Ichinose Y, Ohe Y et al (2012) Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 7:115–121PubMedCrossRef
30.
go back to reference Kimura H, Kasahara K, Kawaishi M et al (2006) Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12:3915–3921PubMedCrossRef Kimura H, Kasahara K, Kawaishi M et al (2006) Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12:3915–3921PubMedCrossRef
31.
go back to reference Kuang Y, Rogers A, Yeap BY et al (2009) Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 15:2630–2636PubMedCentralPubMedCrossRef Kuang Y, Rogers A, Yeap BY et al (2009) Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 15:2630–2636PubMedCentralPubMedCrossRef
Metadata
Title
Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysis
Authors
Zhijun Li
Yongjun Zhang
Wenlong Bao
Chuming Jiang
Publication date
01-12-2014
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 4/2014
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-014-0312-2

Other articles of this Issue 4/2014

Targeted Oncology 4/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine